Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
|Videos|March 23, 2018
APhA Honors Lucinda Maine with Leadership Mentor Award
At the American Pharmacists Association Annual Meeting, Lucinda L. Maine, PhD, RPh, AACP, was honored with the Gloria Niemeyer Francke Leadership Mentor Award.
Advertisement
At the American Pharmacists Association Annual Meeting (
In this clip, Dr. Maine talks about her experiences as a role model and mentor for future leaders in pharmacy.
Advertisement
Related to this article
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5